MedPath

Tipranavir

Generic Name
Tipranavir
Brand Names
Aptivus
Drug Type
Small Molecule
Chemical Formula
C31H33F3N2O5S
CAS Number
174484-41-4
Unique Ingredient Identifier
ZZT404XD09
Background

Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.

Indication

For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort

Withdrawn
Conditions
HIV Infections
First Posted Date
2008-12-10
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT00805857

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Completed
Conditions
HIV Infections
First Posted Date
2008-02-14
Last Posted Date
2014-08-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
42
Registration Number
NCT00615290
Locations
🇫🇷

1182.127.3301 Boehringer Ingelheim Investigational Site, Strasbourg, France

🇫🇷

Boehringer Ingelheim Investigational Site, Villeneuve St G, France

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

First Posted Date
2007-10-01
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
517
Registration Number
NCT00537394
Locations
🇺🇸

Children's National Med. Ctr. ATN CRS, Washington, District of Columbia, United States

🇺🇸

Univ. of Rochester ACTG CRS, Rochester, New York, United States

🇺🇸

UCLA CARE Center CRS, Los Angeles, California, United States

and more 61 locations

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2007-09-18
Last Posted Date
2014-06-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
85
Registration Number
NCT00530920
Locations
🇮🇹

1182.107.39001 Boehringer Ingelheim Investigational Site, Antella (fi), Italy

🇪🇸

1182.107.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain

🇪🇸

1182.107.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain

and more 9 locations

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Completed
Conditions
HIV Infections
Interventions
First Posted Date
2007-09-18
Last Posted Date
2014-04-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
65
Registration Number
NCT00531206
Locations
🇩🇪

Boehringer Ingelheim Investigational Site, Wuppertal, Germany

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Phase 3
Terminated
Conditions
HIV Infections
First Posted Date
2007-08-16
Last Posted Date
2014-05-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
40
Registration Number
NCT00517192
Locations
🇨🇦

1182.71.1002 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada

🇧🇸

1182.71.1016 Boehringer Ingelheim Investigational Site, Nassau, Bahamas

🇵🇹

1182.71.3502 Boehringer Ingelheim Investigational Site, Amadora, Portugal

and more 51 locations

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

Phase 3
Terminated
Conditions
HIV Infections
First Posted Date
2007-03-15
Last Posted Date
2014-05-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
11
Registration Number
NCT00447902
Locations
🇺🇸

1182.99.31 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States

🇫🇷

1182.99.3306K Boehringer Ingelheim Investigational Site, Nantes, France

🇩🇪

1182.99.4909 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany

and more 27 locations

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Phase 3
Terminated
Conditions
HIV Infections
Interventions
Drug: Optimized Background Regimen (OBR)
First Posted Date
2007-02-27
Last Posted Date
2014-06-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
33
Registration Number
NCT00440271
Locations
🇺🇸

1182.98.018 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States

🇺🇸

1182.98.014 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States

🇺🇸

1182.98.004 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States

and more 27 locations

3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2006-01-12
Last Posted Date
2023-12-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
216
Registration Number
NCT00275444
Locations
🇺🇸

Mercer University School of Medicine, Macon, Georgia, United States

🇺🇸

John's Hopkins University, Baltimore, Maryland, United States

🇺🇸

Rush-Presbytarian-St Luke's Medical Center, Chicago, Illinois, United States

and more 41 locations

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Phase 4
Completed
Conditions
HIV-Associated Lipodystrophy Syndrome
Cardiovascular Disease
First Posted Date
2005-09-19
Last Posted Date
2012-04-12
Lead Sponsor
Kirby Institute
Target Recruit Count
80
Registration Number
NCT00192660
Locations
🇦🇺

St. Vincent's Hospital, Sydney, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy